Cytokinetics, Incorporated

Cytokinetics, Incorporated is a biopharmaceutical company headquartered in South San Francisco, California, dedicated to discovering, developing, and commercializing muscle activators and inhibitors. Founded in 1997, the company's mission is to improve the healthspan of individuals living with debilitating cardiovascular and neuromuscular diseases characterized by impaired or declining muscle function.

Cytokinetics' pipeline focuses on addressing conditions such as heart failure, hypertrophic cardiomyopathy (HCM), amyotrophic lateral sclerosis (ALS), and muscular dystrophy. Key investigational and approved medicines include MYQORZO (aficamten), a cardiac myosin inhibitor approved for symptomatic obstructive HCM in the U.S., Europe, and China; omecamtiv mecarbil, a cardiac myosin activator for heart failure with reduced ejection fraction (HFrEF); ulacamten (CK-586), a cardiac myosin inhibitor for heart failure with preserved ejection fraction (HFpEF); and CK-089, a fast skeletal muscle troponin activator for skeletal muscle conditions.

The company is currently transitioning into a global commercial-stage entity following the multi-region approvals and ongoing launch of MYQORZO. Recent milestones include the U.S. commercial launch of MYQORZO and planned European launches, with a goal to achieve over 50% new patient share for MYQORZO by the end of 2026. Cytokinetics reported approximately $1.22 billion in cash, cash equivalents, and investments at the end of 2025, and is anticipating topline results from the ACACIA-HCM trial in Q2 2026. Robert I. Blum serves as the President and CEO.